Abstract Ceramide is a key metabolite in both anabolic and catabolic pathways of sphingolipids. The very long fatty acyl chain ceramides N-(docosanoyl)-sphing-4-enine (Cer(22:0)) and N-(tetracosanoyl)-sphing-4-enine (Cer(24:0)) are associated with multiple biological functions. Elevated levels of these sphingolipids in tissues and in the circulation have been associated with insulin resistance and diabetes. To facilitate quantification of these very long chain ceramides in clinical samples from human subjects, we have developed a sensitive, accurate, and high-throughput assay for determination of Cer(22:0) and Cer(24:0) in human plasma. Cer(22:0) and Cer(24:0) and their deuterated internal standards were extracted by protein precipitation and chromatographically separated by HPLC. The analytes and their internal standards were ionized using positive-ion electrospray mass spectrometry, then detected by multiple-reaction monitoring with a tandem mass spectrometer. Total liquid chromatography-tandem mass spectrometry (LC-MS/MS) runtime was 5 min. The assay exhibited a linear dynamic range of 0.02-4 and 0.08-16 μg/ml for Cer(22:0) and Cer(24:0), respectively, in human plasma with corresponding absolute recoveries from plasma at 109 and 114 %, respectively. The lower limit of quantifications were 0.02 and 0.08 μg/ml for Cer(22:0) and Cer(24:0), respectively. Acceptable precision and accuracy were obtained for concentrations over the calibration curve ranges. With the semiautomated format and short LC runtime for the assay, a throughput of ∼200 samples/day can easily be achieved.
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Introduction
Ceramides consist of a long chain sphingoid base and an amidelinked fatty acid that is either saturated or unsaturated and varies in length from two to 28 carbon atoms. The metabolic pathways responsible for ceramide synthesis include the sphingomyelinase pathway, the de novo synthesis pathway, the exogenous ceramide-recycling pathway, and the salvage pathway [1] . Ceramides have been implicated in regulation of diverse cellular processes, including cell cycle arrest, apoptosis, senescence, and stress responses [2, 3] . These processes may be mediated through ceramide's effect on membrane platforms, including re-organization of rafts and selective trapping of receptors and signaling proteins, or through its role as a second messenger [2] . Formation of ceramides can be induced by different stimuli such as tumor necrosis factor-α, Fas ligand, phorbol ester, heat stress, oxidative stress, ionizing radiation, and chemotherapeutics [4] . Since the different biological effects caused by ceramides depend on the type of fatty acid attached to the sphingoid base, it is important to consider changes in ceramide content in a structure-specific manner when studying its biological functions [5] . N-(docosanoyl)-sphing-4-enine (Cer(22:0)) and N-(tetracosanoyl)-sphing-4-enine (Cer(24:0)) are major ceramide species present in human platelets and plasma [6, 7] , and alterations in levels of these molecular species have been correlated with metabolic disease in humans. In obese women, hepatic steatosis is correlated with increased levels of Cer(22:0) in subcutaneous adipose tissue [8] . Accompanying increases in macrophage inflammatory markers in adipose tissue suggest that these lipids may relate to the pathogenesis of the metabolic derangements. Systemically, Cer(24:0) is increased in the plasma of obese type 2 diabetic subjects compared to controls, and levels correlate inversely with insulin sensitivity [9] . While these human studies are associative, data from animal models demonstrate that de novo synthesized ceramide functions as a mediator of insulin resistance and suggest that this pathway may provide new biomarkers of disease and/or targets for therapeutic interventions [10] .
To gain further insight into the role of these very long chain ceramides in human pathophysiology, an accurate and precise analytical method for determination of Cer(22:0) and Cer(24:0) is required. Numerous methods have been developed for profiling and quantification of individual ceramides in biological matrices [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . including thin-layer chromatography (TLC) [24] , high-performance liquid chromatography (HPLC) [12] , immunochemical methodologies [25] , enzymatic assay [13] , tandem mass spectrometry [22] , liquid chromatography-tandem mass spectrometry (LC-MS/MS) [11, 14-17, 21, 26] , gas chromatography [18, 19] , and gas chromatographymass spectrometry [18, 19, 23] . While assays for Cer(22:0) and Cer(24:0) have previously been reported [14, 16, 26] , these types of assays, however, are not well-suited for clinical application because matrix-based quality control (QC) samples are not used to monitor assay performance and robustness, and sample throughput tends to be low. Here, we describe a highthroughput method for determination of Cer(22:0) and Cer(24:0) that is validated according to the Food and Drug Administration (FDA) bioanalytical method validation guidance [27] and the principles of fit-for-purpose assay method development for biomarker measurement [28, 29] . ]Cer(24:0) (greater than 98 % chemical purity and 97 % isotopic purity) were prepared as described in Electronic Supplemental Material. Formic acid and bovine serum albumin (BSA) were obtained from Sigma-Aldrich (St. Louis, MO). All HPLC solvents (isopropanol and chloroform) were LC-MS grade and were purchased from Honeywell (Morristown, NJ). Milli-Q ultrapure water was prepared inhouse with a Milli-Q Integral Water Purification System (Billerica, MA).
Experimental

Chemicals and reagents
Sample collection
The study was performed in agreement with the 1990 Declaration of Helsinki and subsequent amendments. Fasting plasma samples from control (n=5), obese (n=5), and obese type 2 diabetic (n=4) premenopausal female subjects between the ages of 30 and 55 years were collected from subjects enrolled in the Lipid Biomarkers for Diabetic Complications protocol, which was approved by the Human Studies Committee at Washington University. Diabetes was confirmed by oral glucose tolerance testing and diabetics were treated with oral medications only. From each subject, two samples were obtained 2 weeks apart. De-identified plasma samples were provided for analysis in accordance with Human Studies Committee Guidelines. For preparation of QC samples and standard curves, control human plasma was obtained commercially (BioChemed Services; Winchester, VA).
Stock solution preparation
All the stock solutions (1 mg/ml) were prepared in isopropanol. A working solution containing 200 μg/mL of Cer(22:0) and 800 μg/mL of Cer (24:0) 
Sample preparation
Standards, QCs, blank or study samples (50 μL) were aliquoted into a 96-well (2 mL/well) plate. To each well internal standard/protein precipitation solution (400 μL) was added except that isopropanol/chloroform (9:1) (400 μL) was used for a blank. The plate was vortexed for 3 min, centrifuged for 10 min at 3,000×g, and 250 μL of supernatant transferred to clean 96 wells (1 mL/well) plate with a Tomtec Quadra 96 (Tomtec, Hamden, CT) for LC-MS/MS assay.
LC-MS/MS analysis
LC-MS/MS analysis was conducted on a Shimadzu (Columbia, MD) Prominence UFLC system coupled with an Applied Biosystems/MDS Sciex (Ontario, Canada) 4000QTRAP mass spectrometer using multiple-reaction monitoring (MRM). Separation of Cer(22:0) and Cer(24:0) was carried out at 50°C using a Phenomenex (Torrance, CA) Gemini C6-phenyl analytical column (2×50 mm, 5 μm) connected to a Phenomenex (Torrance, CA) SecurityGuard C18 guard column (4×3 mm) at a flow rate of 0.6 mL/min. The mobile phase consisted of 0.1 % formic acid in water (solvent A), and 0.1 % formic acid in isopropanol (solvent B). The step gradient was as follows: 0-0.5 min, 65 % solvent B; 0.5-2 min, 65 to 90 % solvent B; 2-2.1 min, 90 to 100 % solvent B; 2.1-3 min, 100 % solvent B; 3-3.1 min; 100 to 65 % solvent B; 3.1-5 min 65 % solvent B. The HPLC eluate was directed into the mass spectrometer for data acquisition within the 2-min time window (1.5-3.5 min) in which Cer(22:0) and Cer(24:0) were eluted; elsewhere, eluate was sent to waste to minimize source contamination. The injection volume was 5 μL and the total runtime was 5 min. The ESI source temperature was 300°C; the ESI needle was 5,500 V; the declustering potential was 66 V; the entrance potential was 10 V; and the collision cell exit potential was 10 V. The collision and curtain gas were set at medium and 15, respectively. Both desolvation gas and nebulizing gas were set at 45 L/min and the collision energy was 40 eV. For MRM, the dwell time was set at 50 ms for each of the signal from transitions of m/z 622 to 264 (quantifier for Cer ( 
Quality control samples
A pooled-plasma sample was analyzed to establish the mean concentration of endogenous Cer(22:0) and Cer(24:0) by the LC-MS/MS method. The low (L), medium (M), and high (H) plasma quality control (QC) samples were prepared by spiking Cer(22:0) and Cer(24:0) working solution to yield endogenous level + 0/0, endogenous level + 1.5/6, and endogenous level+3/12 μg/mL, respectively. The lower limit of quantification (LLOQ) sample was prepared in 5 % BSA. The endogenous level+6/24 μg/mL QC, which is also referred to as a dilution quality control (DQC) sample, was higher than the upper limit of quantification (ULOQ: 4/16 μg/mL of Cer(22:0)/Cer(24:0)), and thus was diluted 1:4 with 5 % BSA prior to extraction.
Linearity, precision, and accuracy
The linearity response of analytes was assessed over their respective calibration range from three batches of analytical runs. The precision and accuracy of the assay were determined for each analyte at LLOQ, LQC, MQC and HQC concentration levels in human plasma over the three batch runs. The dilution QC was used to assess the dilution integration. These QC concentrations included the known fortified levels added to the plasma plus the endogenous concentration of analyte. For each QC concentration, analysis was performed in six replicates on each day except for dilution QCs for which three replicates were prepared. Precision and accuracy are denoted by percent coefficient of variance (%CV) and percent relative error (%RE), respectively. The calculation of precision and accuracy is described in Electronic Supplemental Material. The accuracy and precision were required to be within±15%RE of the nominal concentration and ≤15%CV, respectively, for LQC, MQC, HQC, and DQC samples. The accuracy and precision were required to be within±20%RE of the nominal concentration and ≤20%CV for LLOQ samples in the intra-batch and inter-batch assays [27] .
Sample stability
For each analyte, long-term storage, and freeze/thaw stabilities, and stabilities on the bench-top and in the autosampler were determined at the LQC and HQC concentration levels (n=3). Long-term storage stability of analytes in human plasma was tested up to 39 days upon storage at −80°C. Bench-top stability was evaluated from samples that were kept on lab bench at room temperature for 14 h before sample extraction. Freeze/thaw stability was tested by freezing the samples overnight, followed by thawing to room temperature the next day. This process was repeated five times. A standard curve was prepared on the day of analysis when long-term storage, bench-top and freeze/thaw stabilities were measured. In the autosampler, stability was tested over 3 days by injecting the first batch of the validation samples. Stock solution stability was established by quantification of samples from dilution of two stock solutions that have been stored at −20°C for 38 days and at room temperature on the bench for 4 h, respectively, to the final ULOQ solution (4/16 μg/mL of Cer(22:0)/Cer(24:0) in isopropanol). A fresh standard curve was established each time.
Analysis of clinical samples
Samples consisted of calibration standards in duplicate, a blank, a blank with internal standards, QC standards (LQC, MQC, and HQC), and unknown clinical samples were analyzed. The standard curve covered the expected unknown sample concentration range, and samples that exceeded the highest standard could be diluted and re-assayed. In the dilution sample re-assay, a diluted QC in triplicate would be also included in the analytical run. The results of the QC samples provided the basis of accepting or rejecting the run according to FDA guidelines [27] .
Statistics
Results are expressed as mean±S.D. For group comparisons, and the statistical significance of differences in mean values was determined by a two-tailed Student's t test. A p value of 0.05 or less was considered significant. + ion of Cer(22:0) at m/z 622 and proposed structures of the fragment ions are shown in Fig. 1 [31] . The most abundant product ion at m/z 264, arising from loss of fatty acyl chain, was chosen to set up multiple-reaction monitoring (MRM) transition for quantification of Cer(22:0) and Cer(24:0). MRM transitions from [M+H] + to m/z 284 were also recorded for further structure identification. We used a Gemini Phenyl C6 (2×50 mm, 5 μm) column, which provided superb separation within a 5-min runtime.
Results and discussion
LC-MS/MS assay development
Among the major methods typically used for sample clean up, protein precipitation (PPT) generally yields samples with more impurities than liquid-liquid extraction (LLE) and solidphase extraction (SPE). Despite this drawback, we chose PPT because it offers high throughput and enables automated workflows. During PPT method optimization, individual organic solvents (e.g., methanol, acetonitrile, and isopropanol), alone or combined in different ratios with chloroform, were evaluated. The optimized method was precipitation with isopropanol/chloroform (9:1) (see Electronic Supplementary Material Table S1 ). The supernatant was injected directly after it was transferred from the PPT plate to a new plate with liquid handler. The semi-automated method allowed processing ∼200 samples over 2 h.
Surrogate matrix selection for standard curves
One common challenge in biomarker analysis is to select an appropriate surrogate matrix that is free of target analytes and is comparable to unknown sample matrix with respect to matrix effects and extraction efficiency. We used 5 % BSA in water, as matrix to establish standard curve since good linearity and repeatability can be achieved and non-specific binding was not observed. In this study, we were able to construct standard curves from standards prepared in BSA solution and in human plasma, and the deviation of the standard curves were less than 3 % for Cer(22:0) and Cer (24:0) ( Table 1 ). The intercept of the former curve was close to zero, while it is slightly greater than zero for the latter due to the presence of the endogenous analytes.
Extraction efficiency and matrix effects
To evaluate the recoveries of the Cer(22:0) and Cer(24:0) from human plasma and matrix (5 % BSA), signals of Table S2 ). The matrix factors [32] for Cer(22:0) and Cer(24:0) were assessed by comparing the peak response of the ([ 2 H 4 ]Cer(22:0) and [ 2 H 4 ]Cer(24:0)) from post-extraction spiked samples to equivalent pure compound solutions in isopropanol/chloroform (9:1). No significant matrix effects were observed for Cer(22:0) in BSA or Cer(24:0) in BSA and plasma. Although matrix effect was observed for Cer(22:0) in plasma, the coelution of deuterium-labeled internal standard compensated the matrix effect and the accuracy and precision were not affected.
Selectivity
To ascertain the selectivity of the plasma method, blank (BSA solution) with and without internal standard and six independent human plasmas were analyzed. As shown in Fig. 2a and h, the responses of interfering peaks from blank were less than 1 % of that of Cer (22:0) and Cer(24:0) in LLOQ and less than 1 % of that of internal standards. As shown in Fig. 2b and i, the responses of interfering peaks from blank with internal standards were less than 3 % of that of Cer(22:0) and less than 1 % of that Cer(24:0) in LLOQ. Figure 2c and j shows the highest calibrator (ULOQ, 6/24 μg/mL of Cer(22:0)/Cer(24:0)) without internal standards, and the contribution from [M+4+H] + isotope peaks of Cer(22:0) and Cer(24:0) were less than 0.1 % of the those of their internal standards.
All the human plasma used contained endogenous levels of Cer (22:0) (Fig. 2d) and Cer(24:0) (Fig. 2k ). There were no interfering peaks from the human plasma at the retention time and in the MRM channels of the internal standards. Figure 2e and l show the chromatograms of Cer(22:0) and Cer (24:0) in human plasma with internal standards. Figure 2f and m also show chromatograms of the second mass transitions of m/z 622 to 282 for Cer(22:0) and m/z 650 to 282 for Cer(24:0), respectively, that were used for purposes of confirmation. The selectivity was also evaluated by comparison of branching ratio [30, 33, 34] of the mass transitions from six individual blank plasma samples with that of the highest calibrator (ULOQ sample) prepared in isopropanol/chloroform (9:1). The branching ratio is the ratio of peak areas of two mass transitions of Cer(22:0) (m/z 622 to 264/m/z 622 to 280) or Cer(24:0) (m/z 650 to 264/m/z 650 to 280), used to assure specificity of the detection. The selectivity was further confirmed by branching ratio of six individual blank plasma samples within 10 % of the value of the highest calibrator (see Electronic Supplementary Material Table S3 ).
Sensitivity
The LLOQ for Cer(22:0)/Cer(24:0) was prepared in BSA solution at 0.02/0.08 μg/mL, the lowest concentration in the standard curve. The LLOQ samples were processed and analyzed with a calibration curve and QC samples. The intrarun precisions at LLOQ level were 2.7-3.4%CV and 2.8-3.4%CV for Cer(22:0) and Cer(24:0), respectively. The intrarun accuracy levels were −3.2-0.0%RE and −1.0-4.1%RE for Cer(22:0) and Cer(24:0), respectively. The inter-run precision was in the range of 3.2%CV and 3.6%CV for Cer(22:0) and Cer(24:0), respectively. The inter-run accuracy was −1.6%RE and 1.3%RE for Cer(22:0) and Cer(24:0), respectively ( Table 2) . A typical MRM chromatogram at the LLOQ concentration is shown in Figs. 2g and n.
Accuracy and precision
The accuracy and precision of the method were assessed by analyzing QC samples along with a calibration curve on three (24:0). Excellent results were obtained for the calibration curves, as the deviations of the back-calculated concentrations from their nominal values were within 15 % for all the calibration standards in the 3 days of validation. All the QC samples were prepared in human plasma, and the endogenous levels of Cer(22:0) and Cer(24:0) were determined by mean of multiple replicates (n=12). The endogenous levels were used to calculate the nominal concentrations of the spiked (MQC and HQC) and dilution QC (DQC). The DQC was diluted five times with 0.5 % BSA solution before extraction, and followed the procedure for other samples. The results of the QC samples in the three validation runs and dilution integration are shown in Table 2 Table S4 ). The bench-top stability study showed that the Cer(22:0) and Cer(24:0) were stable in human plasma for 14 h at room temperature. The stability of Cer(22:0) and Cer(24:0) were determined to be acceptable in human plasma following five freeze-thaw cycles. For processed samples (autosampler stability), the Cer(22:0) and Cer(24:0) were stable for 3 days at room temperature. The Cer(22:0) and Cer(24:0) were determined to be stable for 38 days at −80°C.
The Cer(22:0) and Cer(24:0) in standard curve matrix and stock solution were stable for 4 h at room temperature and for 38 days at −80°C (see Electronic Supplementary Material Table S5 ). Insulin resistance is a key feature of type 2 diabetes, and numerous studies in both culture and animal models demonstrate that there is a strong association between increasing ceramide levels and defective insulin action in target tissues, especially skeletal muscle and liver [10, [35] [36] [37] [38] . The improvements in insulin sensitivity via exercise training in obese patients are associated with significant reductions in intramyocellular ceramide levels [24, 39] . The very long acyl chain ceramide assay was used to quantify Cer(22:0) and Cer (24:0) in human plasma samples from five control, five obese and four type 2 diabetic women. As shown in Fig. 3 , levels of Cer(22:0) and Cer(24:0) concentrations were significantly elevated in type 2 diabetics compared to controls. There was no difference between obese and diabetic subjects. Although levels trended higher in obese than in controls, this did not meet statistical significance in this small sample size. The ∼2.5-fold higher concentration of Cer(24:0) compared to the Cer(22:0) in plasma was noted and also reported by another group [7] . Plasma ceramide is most likely synthesized in the liver by ceramide synthases (CerS) from sphinganine and acyl coenzyme A (CoA), incorporated into lipoproteins and transported into the plasma. In certain conditions, it may also be formed in the arterial wall from sphingomyelin by the sphingomyelinase [40] . So far, six different mammalian CerS (CerS1-6) have been described. They differ in their tissue-specific expression pattern and in their substrate specificity resulting in the production of ceramides with different N-acyl side chains (Cer(14:0)-Cer(26:0)). The CerS2 and CerS4 are responsible for production of Cer(22:0) and Cer(24:0) [41] . The CerS2 and CerS4 in liver probably have more specificity toward 24:0 acyl-CoA than 22:0 acyl-CoA.
Conclusions
In addition to their potential utility as biomarkers for type 2 diabetes, plasma concentrations of Cer(22:0) and Cer(24:0) in plasma are also associated with mild cognitive impairment [42] , and may be early indicators of Alzheimer's disease progression. We have developed a rapid LC-MS/MS method for quantification of Cer(22:0) and Cer(24:0) in human plasma. The simplicity of the technique (protein precipitation) and its high selectivity for Cer(22:0) and Cer(24:0) renders this method particularly attractive. The assay exhibits a high degree of sensitivity, precision, and accuracy, and is ready to apply to measurement of Cer(22:0) and Cer(24:0) in clinical samples.
